Sjögren-Syndrom: früher diagnostizieren, wirksam behandeln

Was ist neu?

Therapiestudien Fortschritte im Verständnis der Pathophysiologie des primären Sjögren-Syndroms und die Erarbeitung von Aktivitätscores führten zur Entwicklung und Erprobung neuer Therapieansätze. Aktuell laufen mindestens 17 kontrollierte Studien beim primären Sjögren-Syndrom.

Früherkennung Neue Klassifikationskriterien wurden etabliert, mit denen die Erkrankung schon im Frühstadium und bei extraglandulären Manifestationen erfasst werden kann. Die Sonografie der Speicheldrüsen bietet weiteres Potenzial für die Verbesserung der Sensitivität der Diagnostik.

Abstract

Primary Sjögren’s syndrome (pSS) is an autoimmune disease affecting the salivary and lachrymal glands. The patients complain of symptoms of dry eyes and dry mouth, but up to 50 % may additionally develop extraglandular manifestations such as arthritis, vasculitis, polyneuropathy, pulmonary fibrosis or interstitial nephritis. Most therapeutic studies on the glandular manifestations of pSS failed to meet their primary endpoints, possibly since many of the patients had already advanced and irreversible disease.

In recent years several important advances have been made. The role of B and T lymphocytes in the pathogenesis of pSS has been identified. The disease activity scores ESSDAI and ESSPRI were developed and can now be used as endpoints in therapeutical studies. Since then, numerous promising new drugs, mostly affecting B and T lymphocytes, have been studied in clinical trials. New classification criteria have been proposed, which will be an important tool in making a diagnosis in an early disease stage, in which the glandular function may still be normal. It is very likely therefore, that we will soon have efficient therapies, which will be able to stop the disease progression in an early stage of pSS.

Schlüsselwörter

Sjögren-Syndrom - Klassifikationskriterien - Therapie

Key words

Sjögren’s syndrome - classification criteria - therapy

• Literatur

• 1 Qin B, Wang J, Yang Z. et al. Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 1983-1989
• 2 Ramos-Casals M, Brito-Zerón P, Seror R. et al. Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology 2015; 54: 2230-2238
• 3 Vivino FB, Al-Hashimi I, Khan Z. et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999; 159: 174-181
• 4 Vitali C, Bombardieri S, Jonsson R. et al. European Study Group on Classification Criteria for Sjögren’s Syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558
• 5 Seror R, Ravaud P, Bowman SJ. et al. EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis 2010; 69: 1103-1109
• 6 Seror R, Ravaud P, Mariette X. et al. EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren’s syndrome. Ann Rheum Dis 2011; 70: 968-972
• 7 Gong YZ, Nititham J, Taylor K. et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren’s syndrome. J Autoimmun 2014; 51: 57-66
• 8 Mariette X, Seror R, Quartuccio L. et al. Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2015; 74: 526-531
• 9 Ristov J, Espie P, Ulrich P. et al. Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody. Am J Transplant 2018; DOI: 10.1111/ajt.14872. . [Epub ahead of print]
• 10 Verstappen GM, Meiners PM, Corneth OBJ. et al. Attenuation of Follicular Helper T Cell-Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren’s Syndrome. Arthritis Rheumatol 2017; 69: 1850-1861
• 11 Vitali C, Bombardieri S, Jonsson R. et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558
• 12 Shiboski CH, Shiboski SC, Seror R. et al. 2016 American College of Rheumatology/European League against Rheumatism classification criteria for primary Sjögren’s syndrome. Ann Rheum Dis 2017; 76: 9-16
• 13 Seror R, Bowman SJ, Brito-Zeron P. et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open 2015; 1: e000022 . doi: 10.1136/rmdopen-2014-000022